Financial Statements — ZBIO
Balance Sheet
(in millions USD)| Metric | Q2
2026 | Q1
2026 | Q3
2025 | Q2
2025 | Q1
2025 | Q3
2024 |
|---|
| Cash & Equivalents | 196.58 | 500.22 | 115.57 | 44.01 | 196.55 | 360.04 |
| Short-term Investments | 446.55 | 216.98 | 175.32 | 229.27 | 115.83 | 26.76 |
| Total Current Assets | 653.79 | 730.16 | 296.64 | 278.60 | 317.81 | 393.78 |
| Property, Plant & Equipment | 0.02 | 0.03 | 0.05 | 0.06 | 0.07 | 0.15 |
| Total Non-current Assets* | 47.90 | 17.52 | 25.38 | 14.48 | 15.96 | 9.65 |
| Total Assets | 701.69 | 747.68 | 322.02 | 293.08 | 333.77 | 403.43 |
| Accounts Payable | 7.59 | 8.94 | 6.44 | 7.93 | 20.02 | 15.08 |
| Total Current Liabilities | 65.82 | 61.16 | 52.42 | 53.24 | 49.13 | 44.00 |
| Long-term Debt | -- | -- | 72.99 | -- | -- | -- |
| Total Non-current Liabilities* | 388.78 | 350.69 | 73.17 | 0.22 | 0.32 | 0.00 |
| Total Liabilities | 454.59 | 411.85 | 125.59 | 53.46 | 49.45 | 44.00 |
| Retained Earnings | (957.57) | (846.11) | (524.69) | (473.19) | (420.96) | (334.79) |
| Total Stockholder Equity | 247.10 | 335.83 | 196.43 | 239.63 | 284.32 | 359.44 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2026 | Q1
2026 | Q4
2025 | Q3
2025 | Q2
2025 | Q1
2025 | Q4
2024 | Q3
2024 |
|---|
| Total Revenue | 1.00 | -- | 0.00 | 0.00 | 0.00 | 10.00 | 0.00 | 50.00 |
| Research & Development | 62.91 | 60.44 | 55.72 | 34.40 | 43.03 | 34.92 | 49.16 | 33.53 |
| Selling, General & Admin | 15.75 | 16.91 | 15.59 | 13.18 | 12.14 | 12.42 | 11.47 | 7.45 |
| Total Operating Expenses | 108.66 | 77.35 | 237.98 | 52.58 | 55.16 | 47.33 | 60.62 | 40.98 |
| Operating Income | (107.66) | (77.35) | (237.98) | (52.58) | (55.16) | (37.33) | (55.62) | (40.98) |
| Pretax Income | (111.34) | (80.99) | (240.34) | (51.50) | (52.20) | (33.78) | (52.18) | -- |
| Tax Provision | 0.11 | -- | 0.11 | 0.00 | 0.02 | (0.20) | -- | -- |
| Net Income | (111.46) | (80.99) | (240.44) | (51.50) | (52.22) | (33.57) | (52.60) | (38.61) |
| Basic EPS | (1.77) | (1.46) | (5.17) | (1.22) | (1.25) | (0.80) | 16.94 | (5.02) |
| Diluted EPS | (1.77) | (1.46) | (5.17) | (1.22) | (1.25) | (0.80) | 16.94 | (5.02) |
Cash Flow Statement
(in millions USD)| Metric | Q2
2026 | Q1
2026 | Q4
2025 | Q3
2025 | Q2
2025 | Q1
2025 | Q4
2024 | Q3
2024 |
|---|
| Operating Cash Flow | (57.24) | (75.20) | (52.41) | (41.12) | (41.74) | (37.05) | (38.55) | (81.12) |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 | 0.06 |
| Free Cash Flow* | (57.24) | (75.20) | (52.41) | (41.12) | (41.74) | (37.07) | (38.63) | (81.18) |
| Investing Cash Flow | (287.70) | 31.61 | (93.36) | 40.04 | (112.29) | (86.27) | (3.73) | (26.82) |
| Financing Cash Flow | 42.06 | 433.48 | 140.84 | 72.62 | 1.72 | 0.10 | 1.85 | 411.11 |
* Derived from reported values
